Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam.

TypePublic
HQMalvern, US
Founded2006
Size (employees)195 (est)
Websiterecropharma.com
Recro Pharma was founded in 2006 and is headquartered in Malvern, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Recro Pharma

Gerri Henwood

Gerri Henwood

President & Chief Executive Officer
Michael Celano

Michael Celano

COO
Ryan D. Lake

Ryan D. Lake

CFO
Stewart McCallum

Stewart McCallum

Chief Medical Officer
Fred Graff

Fred Graff

Chief Commercial Officer
Randy Mack

Randy Mack

Senior Vice President, Development
Show more

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, (HQ)
490 Lapp Rd
Show all (1)
Report incorrect company information

Recro Pharma Financials and Metrics

Recro Pharma Revenue

Recro Pharma's revenue was reported to be $71.83 m in FY, 2017
USD

Revenue (Q3, 2018)

18.3m

Gross profit (Q3, 2018)

9.8m

Gross profit margin (Q3, 2018), %

53.7%

Net income (Q3, 2018)

(13.3m)

EBIT (Q3, 2018)

(13.6m)

Market capitalization (4-Dec-2018)

151.8m

Closing stock price (4-Dec-2018)

7.1

Cash (30-Sep-2018)

35.8m

EV

170.7m
Recro Pharma's current market capitalization is $151.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

52.0m69.3m71.8m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m

Gross profit

23.9m32.2m33.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m17.1m19.5m21.7m18.3m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m6.9m10.5m12.1m8.5m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m10.2m9.1m9.7m9.8m

Gross profit Margin, %

50%39%42%45%66%44%38%60%46%44%54%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

19.7m19.8m64.5m61.0m

Accounts Receivable

89.6k8.6m10.4m9.7m

Inventories

9.0m1.1m9.8m

Current Assets

20.4m38.7m84.8m87.3m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

29.9m27.8m23.9m16.6m15.7m28.3m14.9m14.8m24.8m19.5m8.7m11.8m46.3m48.9m35.8m

Accounts Receivable

35.8k86.8k80.2k15.0m9.6m12.2m11.5m12.4m12.3m10.1m13.1m9.8m11.7m11.7m

Inventories

9.6m8.6m7.6m6.7m9.8m7.8m6.9m9.9m10.0m8.1m10.2m

Current Assets

30.2m28.1m24.1m17.3m42.4m48.4m36.2m35.2m49.0m77.3m69.8m67.1m79.3m79.0m69.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1m)3.0m(30.2m)(50.1m)

Depreciation and Amortization

1.4k4.1m5.0m4.9m

Inventories

1.3m(325.0k)(1.1m)

Accounts Payable

1.1m2.2m8.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(26.0m)(12.5m)(25.2m)(38.4m)

Depreciation and Amortization

1.3m2.7m1.3m2.5m3.8m1.2m2.4m3.7m1.2m2.5m3.8m

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(1.1m)(189.0k)1.7m(343.0k)

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)
USDY, 2018

EV/EBIT

-12.6 x

EV/CFO

-4.9 x

Debt/Equity

4 x

Debt/Assets

0.3 x

Financial Leverage

13 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Pharma Revenue Breakdown

Embed Graph

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Report incorrect company information

Recro Pharma News and Updates

Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

MALVERN, Pa., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II clinical data for intraven…

Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018

Company to Host Conference Call Today at 8:00 AM ET

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will participate in the following upcoming i…

Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced three poster presentations at PAINWeek 2018, taking place September 4-8, …

Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

Conference Call and Webcast Scheduled for Tuesday, August 7, 2018 at 8:00 a.m. ET Conference Call and Webcast Scheduled for Tuesday, August 7, 2018 at 8:00 a.m. ET
Show more
Report incorrect company information

Recro Pharma Blogs

Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018

Conference Call and Webcast Scheduled for Wednesday, November 7, 2018 at 8:00 a.m. ET MALVERN, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, t…

Recro Pharma Announces PDUFA Date for IV Meloxicam

PDUFA Date Set for March 24, 2019 MALVERN, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that the U.S. Food and Drug Administra…

Recro Announces Expansion of CDMO Service Capabilities

MALVERN, Pa., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the opening of an expanded 24,000 square foot GMP development and high po…

Recro Pharma Provides Regulatory Update for IV Meloxicam

Company Anticipates NDA Resubmission by the End of September 2018 MALVERN, Pa., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today provided a regu…

Recro Pharma Company Life and Culture

Report incorrect company information

Recro Pharma Frequently Asked Questions

  • When was Recro Pharma founded?

    Recro Pharma was founded in 2006.

  • Who are Recro Pharma key executives?

    Recro Pharma's key executives are Gerri Henwood, Michael Celano and Ryan D. Lake.

  • How many employees does Recro Pharma have?

    Recro Pharma has 195 employees.

  • What is Recro Pharma revenue?

    Latest Recro Pharma annual revenue is $71.8 m.

  • What is Recro Pharma revenue per employee?

    Latest Recro Pharma revenue per employee is $368.4 k.

  • Who are Recro Pharma competitors?

    Competitors of Recro Pharma include Sucampo Pharmaceuticals, Array BioPharma and Clinigen Group.

  • Where is Recro Pharma headquarters?

    Recro Pharma headquarters is located at 490 Lapp Rd, Malvern.

  • Where are Recro Pharma offices?

    Recro Pharma has an office in Malvern.

  • How many offices does Recro Pharma have?

    Recro Pharma has 1 office.